Latest News for: janus kinase 3

Edit

Asthma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, ...

GetNews 25 Mar 2025
It further highlights the inactive pipeline products in this space ... AZD4604 is a potent and selective inhibitor of Janus kinase family member, JAK1, intended for inhaled add-on treatment of moderate to severe asthma, uncontrolled on standard of care.
Edit

Treating chronic inflammatory diseases with JAK inhibitors

Science Daily 17 Mar 2025
Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic ...
Edit

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Pharmiweb 10 Mar 2025
In a large, randomized, postmarketing safety study in RA patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor ...
  • 1
×